ANVISA Clears Acoramidis for ATTR-CM, Making Brazil the Sixth Market for Near-Complete TTR Stabilization

Media partner

PHARMA · CARDIO-METABOLIC · MAY 25, 2026 · LATIN AMERICA

Six markets now carry a near-complete TTR stabilizer on their approved drug lists. Brazil joined that group on May 6, when ANVISA granted approval to acoramidis — marketed as BEYONTTRA and developed by BridgeBio — for the treatment of transthyretin amyloid cardiomyopathy. The indication covers all-comers: both wild-type and variant ATTR-CM patients, without genetic stratification.

The approval, according to BridgeBio’s announcement, cited data from the ATTRibute-CM Phase 3 trial. That trial reported a 42% reduction in the composite of all-cause mortality and cardiovascular hospitalizations at Month 30, and a 50% reduction in cardiovascular hospitalizations alone. The trial data also indicated that reductions in cardiovascular events were observable by Month 1 — a finding that, if replicated in real-world settings, could influence clinical decision-making around treatment initiation timing.

System Implications

Brazil’s supplementary health system, regulated by ANS, covers more than 50 million beneficiaries in medical plans, according to ANS enrollment data through December 2023. ATTR-CM is a progressive, often fatal disease that has historically been underdiagnosed in Brazil, in part because its symptoms overlap with more common cardiac conditions. An all-comers label — covering both genetic and non-genetic forms — removes a diagnostic prerequisite that in other markets has functioned as a de facto access filter.

The practical consequence for health plan operators is that coverage criteria will need to be defined without the built-in stratification that a variant-only or wild-type-only indication would have provided. ANS has not issued guidance on mandatory coverage timelines for acoramidis as of the date of this report. Whether the drug enters the mandatory coverage list under ANS Resolution frameworks, and on what timeline, has not been publicly disclosed.

Patient Access

For patients with ATTR-CM in Brazil, the approval represents the first domestic regulatory pathway to a near-complete TTR stabilizer — defined in the trial context as achieving ≥90% TTR stabilization. Prior to this approval, Brazilian patients seeking this class of therapy faced import or compassionate-use pathways, which carry administrative and cost barriers that limit real-world uptake.

The announcement does not specify the launch price for acoramidis in Brazil, nor does it detail whether BridgeBio has initiated reimbursement negotiations with ANS-regulated operators or with the Ministry of Health for potential SUS inclusion. Affordability terms remain undisclosed, and the timeline from regulatory approval to commercially available product has not been confirmed in public materials.

Industry and Payer Implications

BridgeBio’s position as the first near-complete TTR stabilizer approved in Brazil — and the only such product with an all-comers ATTR-CM label across the six markets where it holds approval — appears to establish a first-mover advantage in LATAM’s largest private health market. The pricing and reimbursement terms that BridgeBio negotiates with Brazilian payers will likely function as a regional reference point for any subsequent market-access discussions in Colombia, Mexico, Argentina, and Chile.

For health plan operators and hospital pharmacy committees, the immediate operational requirement is formulary review. An ANVISA-approved product with Phase 3 data supporting a broad indication creates pressure to establish coverage criteria, utilization management protocols, and prior authorization frameworks before prescribing volume builds. The absence of a genetic stratification requirement in the label means that the eligible population is, in principle, larger than it would be under a variant-only indication — a factor with direct actuarial implications for medical loss ratio projections.

Competing TTR-targeting therapies hold approvals in some of the same markets, but the specific competitive landscape in Brazil — including which alternative agents hold ANVISA approval and under what indications — has not been detailed in available public materials at the time of this report.

Regulatory and Legal Considerations

The ANVISA approval is a confirmed regulatory decision. No litigation or enforcement action related to this approval has been identified in public records. The approval is described in BridgeBio’s announcement as covering ATTR-CM broadly, without restriction to a specific genetic subtype — a label scope that, if consistent with the full prescribing information filed with ANVISA, would represent one of the broader ATTR-CM indications among the six approved markets.

The full prescribing information and any risk management conditions attached to the ANVISA approval have not been reproduced in available public materials. Prescribers and payers should consult the official ANVISA product monograph for the complete indication language, contraindications, and any post-marketing commitments BridgeBio may have accepted as conditions of approval.

Counterpoint

The principal counterargument is that regulatory approval in Brazil does not resolve the reimbursement question — and in the Brazilian supplementary health system, that gap can persist for years. ANS mandatory coverage decisions follow their own procedural timeline, which is not automatically triggered by ANVISA approval. Without a defined reimbursement pathway, the all-comers label may be commercially broad on paper while remaining practically inaccessible to the majority of ATTR-CM patients whose plans do not voluntarily add the drug to their formularies.

The case is further complicated by ATTR-CM’s diagnostic underrecognition in Brazil. Even with an approved, commercially available therapy, the bottleneck may lie upstream — in the cardiology and echocardiography infrastructure required to identify ATTR-CM patients before they present with advanced heart failure. An all-comers label expands the eligible population in regulatory terms; it does not expand diagnostic capacity.

Strategic Outlook

Brazil’s approval positions acoramidis as the reference product for ATTR-CM pharmacotherapy in the region. One possible scenario is that BridgeBio uses the Brazilian approval as a regulatory anchor for submissions in other LATAM markets, where ANVISA decisions carry informal persuasive weight even without formal mutual recognition agreements. If this trajectory holds, the pricing terms negotiated in Brazil will shape the ceiling — and potentially the floor — for regional access discussions.

For payers, the more immediate question is whether ATTR-CM will be treated as a rare disease requiring individualized coverage decisions or as a condition with sufficient prevalence to warrant a standardized formulary protocol. The all-comers label, combined with the Month 1 cardiovascular event data, may generate prescriber demand faster than payer infrastructure can respond — a dynamic that has precedent in other high-cost cardiac therapies introduced into the Brazilian supplementary market.

Closing Insight

The all-comers label is not merely a commercial advantage — it is a diagnostic challenge in disguise. Brazilian cardiology practice will need to develop or scale ATTR-CM screening protocols to translate a broad regulatory indication into actual treated patients, and the speed of that clinical infrastructure build will determine whether the approval’s population-level impact matches its trial-data promise.